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Abstract
Background: Pituitary adenoma (PA) is a benign primary tumor that arises from the pituitary gland and is associated
with ophthalmological, neurological and endocrinological abnormalities. However, causes that increase tumor
progressing recurrence and invasiveness are still undetermined. Several studies have shown N-myc downstream
regulated gene 2 (NDRG2) as a tumor suppressor gene, but the role of NDRG2 gene in pituitary adenoma pathogenesis
has not been elucidated. The aim of our research has been to examine NDRG2 mRNA expression in PA and to
determine the associations between the NDRG2 gene epigenetic changes and the development of recurrence or
invasiveness of PA and patient clinical data.
Methods: The MS-PCR was used for NDRG2 promoter methylation analysis and gene mRNA expression levels were
evaluated by qRT-PCR in 68 non-functioning and 73 functioning adenomas. Invasiveness was evaluated using magnetic
resonance imaging with Hardy’s modified criteria. Statistical analysis was performed to find correlations between
NDRG2 gene mRNA expression, promoter methylation and patient clinical characteristics and PA activity.
Results: The NDRG2 mRNA expression was significantly lower in the case of acromegaly (GH and IGF-1 hypersecretion)
than in other diagnoses of PAs (p < 0.05). Also, the NDRG2 expression was significantly higher in prolactinoma
(PRL hypersecretion) than in in other diagnoses of PAs (p < 0.05). The promoter of NDRG2 was methylated in 22.69%
(12/58 functioning and 15/61 non-functioning) of patients with PA. However, the NDRG2 gene mRNA expression was
not significantly related to its methylation status. Clinical factors, such as: age, gender, relapse and diagnoses of Cushing
syndrome were of no significance for NDRG2 promoter methylation and mRNA expression levels, as well as secreting or
non-secreting PAs and the invasiveness of PAs.
Conclusion: The different NDRG2 promoter methylation and expression levels in PA samples showed tumor
heterogeneity and indicates a potential role of this gene in pituitary adenoma pathogenesis, but the corresponding
details require intensive research.
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Background
Pituitary adenoma (PA) is a common intracranial neo-
plasm with reported estimated prevalence rates to be
14.4% to 22.5% in pooled autopsy and radiological
series, respectively [1]. PAs are generally benign but
can behave clinically in different ways. Some of pituit-
ary tumors are hormonally inactive, others secrete hor-
mones in excess, and some of PAs can cause morbidity
because of dysregulation of hormone production and/
or symptoms of mass effect [2, 3]. The pituitary gland
is localized in a dual bag attached to the inferior aspect
of the diaphragm of the sella and surrounded by venous
spaces that correspond laterally to the cavernous si-
nuses [4]. Cavernous sinus invasion has an influence on
the management and prognosis of PA [5], because dual
wall invasion usually implies partial surgical removal of
the tumor [6]. Early prediction of which pituitary tumor
will recur and/or exhibit an invasive phenotype remains
difficult despite the introduction of several tissue-based
molecular markers [7].
Associations between tumors (including glioblastoma,
gastric cancer, colorectal cancer, breast and liver cancers,
meningioma, bladder and thyroid cancers) and N-myc
downstream-regulated gene 2 (NDRG2) have been
reported in numerous studies [8–16]. NDRG2 is a mem-
ber of the NDRG family, which consists of NDRG1,
NDRG2, NDRG3 and NDRG4 [17] and is located at
chromosome 14q11.2, a region that has been reported to
harbor a tumor suppressor gene [18]. NDRG2 is highly
expressed in the brain and skeletal muscle, while it is
marginally expressed or almost undetectable in the sev-
eral human cancer cell lines [17, 19]. NDRG proteins are
reported to be involved in cell proliferation, differenti-
ation, migration, invasion and stress response [19]. It
was shown that NDRG2 reduce tumor cell proliferation
in glioblastomas [20]. Also, NDRG2 upregulation was
associated with Alzheimer's disease or cerebral ischemia
[21, 22]. Several studies have shown NDRG2 promoter
CpG island methylation and down-regulation in liver
[13], gastric [10], colorectal cancers (CRC) [23, 24],
glioblastomas [8, 9] and anaplastic meningioma [25].
However, NDRG2 promoter methylation and mRNA ex-
pression levels in PAs has not been investigated.
The aim of this study was to determinate aberrant pro-
moter methylation and mRNA expression of NDRG2 in
PAs and to evaluate the associations between the methyla-
tion profile of gene, mRNA expression, patients’ clinical
characteristics and tumor invasiveness and recurrence.
Methods
Description of subject
One hundred forty one pituitary adenoma tissues and
clinical patient data were collected at the Department of
Neurosurgery of Hospital of Lithuanian University of
Health Sciences between 2010 and 2016. Tumor tissues
were frozen in liquid nitrogen immediately after their
surgical resection. The age at the time of the operation,
gender, relapse, size and diagnoses of Cushing syndrome,
acromegaly or prolactinoma were collected for each
patient. The endocrinological features were: 73 function-
ing and 68 nonfunctioning adenomas. According to the
clinical findings functioning adenomas were: 7 growth
hormone (GH) - secreting adenomas, 2 insulin-like grow
factor 1 (IGF-1) - secreting adenomas, 1 cortisol (COR)
- secreting adenoma, 44 prolactin (PRL) - secreting ad-
enomas, 1 adrenocorticotropic hormone (ACTH) - se-
creting adenoma and 18 adenomas secreting more than
one hormone. According to tumor size all PAs were
macroadenomas (greater than 10 mm).
Invasion of pituitary adenomas were analyzed using
MR imaging findings and classified according to Hardy
classification, modified by Wilson [5]. The Knosp classi-
fication system was used to quantify the invasion of the
cavernous sinus [6]. Invasiveness was established in 71
patients with pituitary adenoma. From them, 51 invasive
and 20 non-invasive PAs were found.
Nucleic acid extraction
Tissue specimens were pulverized and stored at -80 °C
until DNA and RNA was obtained. Genomic DNA was
extracted from 119 PA specimens by SDS/proteinase K
treatment, followed by phenol–chloroform extraction
and ethanol precipitation. The remaining 22 samples
were missing because of containing too small an amount
of tumor tissue. All the samples were stored at -20 °C
until DNA was modified with sodium bisulfite.
Total RNA was extracted from 141 PAs using Trizol
reagent, according to the manufacturer’s protocol
(Ambion, Life Technologies) and stored at -80 °C until
cDNA synthesis. However, 10 mRNA samples were lost
because the concentrations for cDNA synthesis were too
small. The genomic DNA and RNA concentrations and
purity was determined using Nanodrop spectrophotom-
eter (Eppendorf ). For pure DNA, A260/280 is ~1.8 and
for pure RNA A260/280 is ~2.
Bisulfite Modification and MS-PCR
Extracted genomic DNA of 119 PA samples was modi-
fied with EZ DNA methylation kit™ (Zymo Research), ac-
cording to the manufacturer’s instructions. The sodium
bisulfite treated DNA was eluted in 40 μL of nuclease-
free water.
After bisulfite modification, the methylation-specific
polymerase chain reactions (MS-PCR) were performed
in 15 μl of 7.5 μL Maxima® Hot Start PCR Master Mix
(ThermoFisher Scientific) with Hot Start Taq DNA poly-
merase, 10 pmol of each primer (Metabion International
AG) and nuclease-free water. Primers for methylated
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NDRG2 allele were: 5'-AGAGGTATTAGGATTTTGGG
TACG-3' (forward) and 5'-GCTAAAAAAACGAAAAT
CTCGC-3' (reverse) and for unmethylated allele: 5'-
AGAGGTATTAGGATTTT GGGTATGA-3' (forward)
and 5'-CCACTAAAAAAACAAAAATCTCACC-3' (re-
verse), according to the published data [23]. The reac-
tion was hotstart at 95 °C for 5 min. The amplifications
were carried out in a thermal cycler (Eppendorf ) for
38 cycles, each of which consisted of denaturation at
92 °C for 15 s, annealing at 60 °C for 30 s, and extension
at 72 °C for 15 s, followed by a final 5 min extension at
72 °C. For each set of methylation-specific PCR reactions
methylated (Bisulfite-Converted Universal Methylated
Human DNA Standard (Zymo Research, USA)), unmethy-
lated (human blood lymphocyte DNA, treated with
bisulfite) and negative (nuclease-free water) controls were
included in all reactions.
The MS-PCR products were analyzed by electrophore-
sis on a 2% agarose gel stained with ethidium bromide
and visualized under UV illumination.
cDNA synthesis and qRT-PCR
First-strand cDNA was produced from total RNA by
using RevertAid H Minus M-MuLV Reverse Transcriptase
(ThermoFisher Scientific) and random hexamer primers
(ThermoFisher Scientific), according to the manufacturer’s
protocol. Negative controls were prepared as above, but
without Reverse Transcriptase.
For the NDRG2 gene mRNA expression, Quantitative
real-time PCR (qRT-PCR) was performed using the SYBR
Green chemistry in a Real-Time PCR System “Applied
Biosystems 7500 Fast” (Applied Biosystems, USA). The
12 μl reaction mixture contained of 6 μl Maxima SYBR
Green/ROX qPCR Master Mix (2×) (ThermoFisher Scien-
tific), 15 ng of the cDNA, nuclease-free water and gene-
specific primers: NDRG2 forward 5`-AGAGCTAC
GACCTGAC-3`, reverse 5`-AGCACTGTGTGTACAG-3`
resulting in a 128 bp PCR amplicon to a total concentration
of 0.6 μM. The housekeeping gene β-actin was used as an
internal control with primers: forward 5`-CATTACAC
ATCCAACC-3`, reverse 5`-GGAGTCAGCCTGAGGA-3`,
resulting in a 184 bp PCR amplicon to a total concentration
of 0.1 μM. The NDRG2 and β-actin primers were designed
according to the published data [26]. The PCR amplifica-
tion was performed after denaturation step at 95 °C for
10 min followed by 40 cycles, each of which consisted of
denaturation at 92 °C for 30 s, annealing at 60 °C for 30 s,
and extension at 72 °C for 30 s, and a final step for the
generation of a melting curve to distinguish between the
main PCR product and primer-dimers. All measurements
were performed in triplicate.
The comparative 2-ΔΔCt method was used for the calcula-
tions of NDRG2 gene mRNA expression. The comparison
was carried out between PA normalized threshold cycle
(Ct) values and healthy human brain (RHB) normalized Ct
values: ΔΔCt = (Ct,NDRG2 - Ct,β-actin)PA sample x - (Ct,NDRG2 -
Ct,β-actin)RHB [27]. The final result was given as log2(2
-ΔΔCt)
calculation.
For standard curve design, RHB “FirstChoice Human
Brain Reference RNA” (Ambion, cat. No. AM6050) was
used. Standard curve parameters for NDRG2 were:
efficiency 99.71%, R2 0.994, slope −3.33; for β-actin were:
efficiency 100.08%, R2 0.997, slope −3.32.
Statistical analysis
The SPSS Statistics 19 (SPSS Inc., Chicago, IL) software
package was used for statistical analysis. Chi-square test
was used to evaluate associations among NDRG2 gene
promoter methylation, mRNA expression levels and clin-
ical characteristics (age, gender, relapse, Cushing syn-
drome, acromegaly, prolactinoma, invasiveness, secreting
and non-secreting pituitary adenomas and hormone
groups). The correlation between NDRG2 gene expression
and methylation and the other clinical factors were evalu-
ated by use of the Mann-Whitney test. Kruskal–Wallis
test was used to reveal the difference across medians of
NDRG2 mRNA expression in all hormone groups. The
significance level was defined as p value less than 0.05.
Results
NDRG2 gene methylation frequency in PAs and
associations with patient clinical data
Methylation specific PCR analysis was performed to
determine the methylation status of NDRG2 gene in 119
PA samples (Fig. 1c). The gene was methylated in
22.69% (27/119) of cases. Representative chart is shown
in Fig. 1a. These results indicate that NDRG2 gene has
low methylation status in PAs.
To characterize the correlation between methylation
of NDRG2 promoter and clinical features of PAs, several
clinicopathological characteristics including age, gender,
relapse, invasiveness, diagnoses of acromegaly, prolacti-
noma and Cushing syndrome were compared between
methylated and unmethylated NDRG2 promoter groups.
However, Chi-square test showed that methylation of
NDRG2 promoter was not associated with any of this
clinical data (p > 0.05) (Table 1).
We then analyzed the relationship between NDRG2
promoter methylation and PA hormonal activity (Fig. 1b).
The histogram of hormones distribution in methylated
and unmethylated gene groups revealed that hypersecre-
tion of PRL, IGF-1, GH, ACTH and more than one hor-
mone mostly occur in PAs with unmethylated promoter
of NDRG2 gene. Also, in most cases nonfunctioning PAs
have unmethylated NDRG2 gene. However, the data
showed no statistically significant differences between
these groups (p > 0.05) (Table 1).
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NDRG2 gene expression in PAs and associations with
NDRG2 promoter methylation and patient clinical data
The expression of NDRG2 mRNA in 131 PAs was deter-
mined by qRT-PCR method using the SYBR Green
chemistry. The values were normalized with internal β-
actin control. To investigate the correlation between
NDRG2 promoter methylation and mRNA expression,
statistical analysis was performed in 109 PA samples that
have the values of methylation and expression. However,
Mann-Whitney test showed no significant differences of
NDRG2 mRNA expression between the group of
NDRG2 methylation samples (23 tumors) and the group
of unmethylated NDRG2 gene (86 tumors, p = 0.323).
We then analyzed the correlation between NDRG2
gene mRNA expression and patient clinical characteris-
tics. Using the Mann-Whitney test, we found that the
expression of NDRG2 had no correlation with age, gen-
der, presence or absence of repeated surgery, secreting
or non-secreting PAs and Cushing syndrome (p = 0.076,
p = 0.545, p = 0.783, p = 0.927 and p = 0.980, respect-
ively). Nevertheless, NDRG2 expression was increased
with diagnoses of prolactinoma and decreased with diag-
noses of acromegaly, compared to patients with other
symptoms (p < 0.05) (Fig. 2a, b).
To further investigate whether NDRG2 gene mRNA
expression was associated with hormones, we compared
medians of NDRG2mRNA expression in PRL, IGF-1, GH,
ACTH, COR and multi hormone groups and nonfunc-
tioning PAs (Fig. 3a). Kruskal–Wallis test revealed that the
medians of NDRG2 mRNA expression in all hormone
groups statistically differ (p < 0.05), and the box plots
showed the tendency that GH-secreting, ACTH-secreting
and more than one hormone secreting PAs are at lower
gene expression level than other hormone groups. To spe-
cify these findings, we then analyzed whether the
hormone groups and nonfunctioning PAs reflect on ex-
pression levels of NDRG2 gene. For this matter, the
NDRG2 mRNA expression values were divided into three
gene mRNA expression groups: “low” - values 1.0-fold
lower than the NDRG2 gene mRNA expression median,
“medium” - values ranging in between “low” and “high”,
and “high” - values 1.0-fold higher than the gene median)
As shown in Fig. 3b, distribution of hormones in NDRG2
expression levels were different. In most cases PRL hyper-
secretion was detected with medium NDRG2 gene expres-
sion level (p < 0.05). IGF-1, COR, GH, and ACTH
hormones showed no statistically significant differences
(p = 0.730, p = 0.172, p = 0.075, p = 0.379, respectively) as
well as multiple (more than one hormone) and non-
secreting PAs (p = 0.096, p = 0.584, respectively). Never-
theless, the histogram of hormone groups distribution
showed a tendency, that the hypersecretion of IGF-1 hor-
mone mostly occur with medium and low NDRG2 gene
expression levels, COR - with high NDRG2 mRNA
expression level, GH, ACTH and multiple – at low gene
expression level (Fig. 3b).
Finally, we analyzed the relationship between NDRG2
gene promoter methylation, mRNA expression, and inva-
siveness of 71 pituitary adenomas (51 invasive and 20
noninvasive). However, the analysis (Chi-square and
Mann-Whitney test) showed no significant differences be-
tween these groups (p = 0.452, p = 0.472, respectively).
Additionally, secreting and non-secreting PAs also had no
correlations with invasiveness (p = 0.571). We also wanted
Fig. 1 Analysis of NDRG2 gene promoter methylation in PA samples. a Methylation frequency (%). b Hormone distribution of PAs in methylated and
unmethylated NDRG2 promoter groups. PRL – prolactin, IGF-1 – insulin-like grow factor 1, GH – growth hormone, ACTH – adrenocorticotropic
hormone, multiple – PAs secreting more than one hormone, NS – non-secreting PAs. c Representative MS-PCR for NDRG2 in PA samples. M indicates
amplification of methylated alleles, U unmethylated alleles. M cont. – positive methylation control (Standard Bisulfite Converted Universal Methylated
Human DNA), U cont. – negative methylation control (normal human peripheral lymphocytes), H2O – water control, I-VI designate PA samples
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to reveal the tendency of invasiveness in PRL, IGF-1, GH,
COR, ACTH and more than one hormone secreting PAs.
In addition to this, the dot plot analysis was performed
(Fig. 4). The comparison showed that the means of
NDRG2 gene mRNA expression of hormones in invasive
and non-invasive tumor groups were various. The lowest
NDRG2 expression was detected in PAs secreting more
than one hormone, and the highest in PRL-secreting and
non-secreting pituitary adenomas (Fig. 4).
Discussion
Pituitary adenoma is a common benign monoclonal neo-
plasm [28]. Early prediction of which pituitary tumors
will recur and/or exhibit an invasive phenotype remains
difficult [7]. NDRG2 gene may be a promising target for
cancer, because NDRG2 down-regulation is associated
with cancer development and progression, including
such features as malignant clinical manifestations and
increased pathological grade. Moreover, this gene is a
relevant biomarker for predicting aggressive behavior,
tumor recurrence and overall patient survival [29].
Therefore, should be further studies to show that
NDRG2 up-regulation may be a promising therapeutic
strategy for the treatment of cancer and that might be
associated with PA development, as well.
We began our study by defining NDRG2 promoter
methylation status in PA samples, including all the clinic-
ally functioning and hormonally inactive types. We have
determined 22.69% (27/119) NDRG2 methylation fre-
quency. These results indicate that NDRG2 gene has low
methylation status in PAs. A number of studies using vari-
ous techniques have shown that epigenetic silencing of
the NDRG2 promoter has been found in the majority of
primary tumors, and different cancer cell lines and other
tumor tissues such as glioma (46.3 - 62%), primary gastric
(54%) and colorectal carcinoma (64.28%) cancers [8–11].
NDRG2 promoter methylation was observed to be associ-
ated with the invasiveness in gastric and colorectal cancer
and with the aggressiveness of glioma tumor [8–10]. How-
ever, our analysis has hown no significant association
between NDRG2 gene methylation and pituitary adenoma
invasiveness. Meanwhile, we have demonstrated that hy-
persecretion of PRL, IGF-1, GH, ACTH hormones appear
with a methylated NDRG2 gene more often than with an
unmethylated gene. Also, in most cases nonfunctioning
PAs have an unmethylated NDRG2 gene. However, the
mechanisms related to this are still unknown.
Moreover, previous studies have shown that NDRG2
mRNA expression is low in numerous types of tumor tis-
sues and cancer cell lines, and is a novel tumor suppressor
candidate gene [8, 12–16]. It was observed that NDRG2 ex-
pression loss is significantly correlated with aggressive
tumor behaviors such as late tumor-node-metastasis stage,
differentiation grade, portal vein thrombi, infiltrative growth
pattern, nodal/distant metastasis, as well as shorter patient
survival rates in liver cancer [13]. Also, NDRG2 overexpres-
sion can inhibit tumor growth and invasion in vitro in blad-
der and breast cancer [12, 15]. Meanwhile, our results have
showed no correlation between NDRG2 gene mRNA
Table 1 Relationship between NDRG2 promoter methylation,
patient clinical characteristics, PA invasiveness and NDRG2
mRNA expression
NDRG2 gene methylation
Number of patients M (%) U (%) p-value
Cases 119 27 (22.69) 92 (77.31)
Age (years)
≤60 48 13 (27.08) 35 (72.92) 0.368
>60 70 14 (20.00) 56 (80.00)
Gender
Female 68 15 (22.06) 53 (77.94) 0.850
Male 51 12 (23.53) 39 (76.47)
PA function
Secreting 61 15 (24.59) 46 (75.41) 0.612
Non-secreting 58 12 (20.69) 46 (79.31)
Relapse
Appear 10 2 (20.00) 8 (80.00) 0.832
None 109 25 (22.94) 84 (77.06)
Prolactinoma
Appear 37 9 (24.32) 28 (75.68) 0.952
None 24 6 (25.00) 18 (75.00)
Acromegaly
Appear 12 4 (33.33) 8 (66.67) 0.433
None 49 11 (22.45) 38 (77.55)
Cushing syndrome
Appear 1 0 (0.00) 1 (100.00) 0.565
None 60 15 (25.00) 45 (75.00)
Hormones
PRL 37 9 (24.32) 28 (75.68) 0.801
IGF-1 2 0 (0.00) 2 (100.00) 0.401
GH 6 2 (33.33) 4 (66.67) 0.639
ACTH 1 0 (0.00) 1 (100.00) 0.556
Multiple 13 4 (30.77) 9 (69.23) 0.616
Invasiveness
Invasive 41 10 (24.39) 31 (75.61) 0.452
Non-invasive 19 3 (15.79) 16 (84.21)
NDRG2 mRNA expression
Low 22 3 (13.64) 19 (86.36)
Medium 50 13 (26.00) 37 (74.00) 0.458
High 37 7 (18.92) 30 (81.08)
M methylated, U unmethylated, PRL prolactin, IGF-1 insulin-like grow factor 1,
GH growth hormone, ACTH adrenocorticotropic hormone, multiple PAs
secreting more than one hormone
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expression and pituitary adenoma invasiveness. The mech-
anism of NDRG2 expression in pituitary adenoma prolifera-
tion and invasion has not yet been reported, making it
necessary to further elucidate the role of NDRG2 gene in
pathogenesis of PA.
In addition, we have analyzed the associations of NDRG2
gene mRNA expression with clinical features of PAs. Our
study has revealed that in the case of acromegaly, NDRG2
gene mRNA expression is significantly lower than in other
diagnoses of PAs. It is known that acromegaly is an
insidious disorder characterized by excess secretion of
growth hormone and elevated circulating levels of insulin-
like growth factor-I [30], and in our examination, in most
cases the hypersecretion of GH and IGF-1 hormones were
determined with low NDRG2 gene expression level as well.
Moreover, NDRG2 gene mRNA expression is significantly
higher with diagnoses of prolactinoma than in other diag-
noses of PAs, and in most cases the hypersecretion of PRL
hormone that causes prolactinoma have been detected
with medium NDRG2 expression level. These results are
Fig. 2 NDRG2 gene expression associations with diagnoses of prolactinoma and acromegaly. a Box plots of relative NDRG2 expression associated
with diagnoses of prolactinoma. b Box plots of relative NDRG2 expression associated with diagnoses of acromegaly. None – no diagnoses of
acromegaly. The line inside each box represents the median, the lower and upper edges of the boxes represent the 25th and 75th percentiles,
respectively, and upper and lower lines outside the boxes represent minimum and maximum values (error bars). The Mann-Whitney test showed,
that the NDRG2 expression level was increased with diagnoses of prolactinoma and decreased with diagnoses of acromegaly (p < 0.05)
Fig. 3 NDRG2 gene expression associations with PAs hormones. a Box plots of medians of NDRG2 mRNA expression in PRL, IGF-1, GH, ACTH,
COR, multiple hormone groups and nonfunctioning PAs. The line inside each box represents the median, the lower and upper edges of the
boxes represent the 25th and 75th percentiles, respectively, and upper and lower lines outside the boxes represent minimum and maximum
values (error bars). PRL – prolactin, IGF-1 – insulin-like grow factor 1, GH – growth hormone, ACTH – adrenocorticotropic hormone, multiple – PAs
secreting more than one hormone, NS – non-secreting PAs. b Hormones distribution in low, medium and high NDRG2 expression levels. Significantly
increased amount of PRL hormone was observed at medium NDRG2 mRNA expression level (* p < 0.05)
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consistent with previous reports that the expression of
NDRG2 is regulated by many hormones, including adrenal
steroids [31], dexamethasone [32], insulin [33], androgen
[34] and aldosterone [35]. It was also shown that hormone
estrogen can enhance the expression of NDRG2 and may
influence Na+/K + -ATPase activation as well as ion trans-
port in salivary glands, brain, heart, skeletal muscle, and
kidney where Na+/K + -ATPases were enriched [36]. Also,
in human and in animal models estrogen stimulates PRL
secretion in vitro and induces PRL adenomas in vivo [37].
However, more studies for signal pathway are needed to
show the mechanism underlying and the significant results
we showed in this study.
Conclusion
This is the first study that has demonstrated the NDRG2
gene promoter methylation and mRNA expression in
patients with diagnoses of pituitary adenoma and analyzed
the relationships between NDRG2 epigenetic changes and
the association with PA clinical features including patient
age, gender, relapse, hormone groups, invasiveness, diagno-
ses of prolactinoma, acromegaly and Cushing syndrome.
Our data have revealed that in the case of acromegaly,
NDRG2 gene mRNA expression is significantly lower than
in other diagnosis of PAs and PA that secretes hormones
GH and IGF-1 hormones have low NDRG2 gene expres-
sion level as well. Moreover, NDRG2 gene expression is sig-
nificantly higher with diagnoses of prolactinoma than in
other diagnosis of PAs. Therefore, there is need for inten-
sive research to confirm our findings and justify the
hypothesis that NDRG2 could be a diagnostic marker for
diagnosis of prolactinoma and acromegaly in PAs.
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